Your Independent Source for Business & Financial News

LABORATORY INDUSTRY REPORT®

Kimberly Scott, Senior Editor, kscott@ioma.com

Issue 10-06/June 2010

HIGHLIGHTS

LabCorp to Acquire Westcliff, Diamond Labs
Purchase Increases Market Share in California

Laboratory Corporation of America's pending acquisition of Westcliff Medical Laboratories (Santa Ana, Calif.) and Diamond Reference Laboratory (Diamond Bar, Calif.) is expected to increase the company's share of the $2 billion California lab market by about 5 percent.

LabCorp (Burlington, N.C.) said in late May that it had agreed to acquire Westcliff for $57.5 million, just 0.59x 2009 revenue of $97 million. Westcliff filed for Chapter 11 bankruptcy on May 19 and was offered for sale to numerous potential buyers, according to Kemp Dolliver, managing director of AvondalePartners LLC, an investment banking firm based in Nashville, Tenn., who said the $57.5 million was "a bargain price for LabCorp."

Westcliff reported losses of $13 million and $84 million in 2009 and 2008, respectively. The company has struggled in recent years since being acquired by BioLabs Inc. in June 2006. With funding from Parthenon Capital Partners, BioLabs acquired both Westcliff and Health Line Clinical Laboratories (Burbank, Calif.), which were consolidated under the Westcliff name.

Continued on page 2

Congress to Examine DTC Genetic Test Kits

Lawmakers on the House Energy and Commerce Committee are beginning to look more closely at direct-to-consumer genetic test kits sold over the Internet and in retail locations.

Rep. Henry Waxman (D-Calif.) and three others lawmakers on May 19 sent a letter to executives of Pathway Genomics Corp. (San Diego), 23andMe Inc. (Mountain View, Calif.), and Navigenics (Foster City, Calif.) requesting information on the validity and accuracy of the tests they sell.

Specifically, the committee is requesting:

- A chart listing the conditions, diseases, consumer drug responses, and adverse reactions for which they test;
- All policy documents, training materials, or written

Continued on page 7

■ **LABCORP TO ACQUIRE WESTCLIFF**, *from page 1*

"The BioLabs acquisition was a difficult one, as both Westcliff (known for price discipline) and BioLabs (known for price discounting) had differing pricing strategies and corporate cultures," says Dolliver. "The combined company only achieved modest EBITDA margins."

In an unrelated transaction, LabCorp has agreed to acquire independent lab Diamond Reference Laboratory (Diamond Bar, Calif.), which had revenue of $10 million in 2009.

Acquisitions Viewed as Positive

Dolliver views the Westcliff and Diamond acquisitions as positives for LabCorp. While the Westcliff deal could be a small drag to LabCorp's earnings per share (EPS) initially, he expects LabCorp to integrate operations quickly. Assuming Westcliff earnings before interest, taxes, depreciation, and amortization (EBITDA) margins reach 25 percent to 30 percent, he estimates an annual EPS boost of 10 to 15 cents per share. For now, Avondale is maintaining its EPS estimates of $5.47 for 2010 and $6.23 for 2011.

LabCorp management continues to view the mergers and acquisitions (M&A) environment as quite attractive as valuations have declined, notes Dolliver. Many labs are currently for sale and multiples have declined from more than 2x revenues to 1 to 1.5x revenues. Because the size of potential targets is quite large ($500 million plus), Dolliver says he remains concerned about dilution risk.

Avondale is maintaining its market perform rating and $84 price target for LabCorp, assuming a target multiple of 15x 2010 EPS of $5.47. "We expect the company to continue to post low-to-mid single-digit organic revenue growth and generally stable margins," says Dolliver. "The redeployment of free cash flow should drive low-double-digit EPS growth long term. We expect 2010 and 2011 EPS growth above this level as the dilution from the Monogram acquisition eases in late 2010." LabCorp acquired Monogram (South San Francisco, Calif.) for $155 million in July 2009.

Aurora Diagnostics Files $150M IPO

Aurora Diagnostics, a diagnostic lab and anatomic pathology company based in Palm Beach Gardens, Fla., has filed for a $150 million initial public offering of stock. The company plans to trade on Nasdaq under the symbol "ARDX."

The company was founded in 2006 as a platform for the acquisition and integration of anatomic pathology and other diagnostic laboratory businesses. It is owned in part by Summit Partners (51 percent), KRG Capital Partners (34 percent), and company management (15 percent). Pricing and additional terms of the IPO have not been disclosed.

The majority of Aurora's revenues in 2009 were derived from physicians providing diagnostic services in the nonhospital outpatient channel of the anatomic pathology market. The company maintains 36 exclusive contracts with hospitals

under which it provides outpatient professional anatomic pathology services. It also provides medical director services and, for some hospitals, technical slide preparation services.

'The success of our business model and the value of our specialized diagnostic service offerings are reflected in our significant growth allowing us to reach $171.6 million in annual revenues in 2009.'
— Aurora Diagnostics

"The success of our business model and the value of our specialized diagnostic service offerings are reflected in our significant growth allowing us to reach $171.6 million in annual revenues in 2009," says the company in a filing with the Securities and Exchange Commission (SEC). "Through a combination of organic growth and strategic acquisitions, we have achieved a scale allowing us to provide diagnostic services to the patients of our approximately 10,000 referring physicians, generating approximately 1.6 million accessions in 2009. With 19 primary locations across the United States, we have achieved a national footprint and a leading presence in our local markets upon which we are continuing to build a more integrated and larger-scale diagnostics company."

Through March 31, 2010, Aurora has acquired 17 diagnostic services companies throughout the United States. The most recent acquisition, in November 2009, was a pathology practice for $15.3 million.

Aurora Diagnostics' Financials ($000)

	2007	2008	2009
Net Revenue	$63,451	$157,850	$171,565
Net Income	479	10,670	9,002
Adjusted EBITDA	18,712	$1,390	55,454

Source: Aurora Diagnostics

According to a company filing, Aurora processed approximately 1.6 million accessions from 10,000 referring physicians in 2009. Net revenues increased $13.7 million or 8.7 percent to $171.6 million for the year ended Dec. 31, 2009, from $157.9 million for the year ended Dec. 31, 2008. Organic revenues increased $11.5 million or 7.7 percent from $150.2 million to $161.8 million, and the remaining increase of $2.2 million reflects the impact of the 2008 and 2009 acquisitions.

The organic revenue growth of $11.5 million resulted from a 4.5 percent increase in the volume of accessions and a 3 percent increase in the average revenue per accession. Average revenue per accession increased 3 percent from about $106 to $109 resulting from a combination of an increase in reimbursement and the ordering of additional tests for accession related to cervical screenings.

While Aurora anticipates continued organic growth in annual accession volumes of 5 percent to 10 percent, it also expects the average revenue per accession to decline as the result of a number of factors, including a trend toward referring physicians performing technical and/or professional components of their diagnostic services in their offices, which results in a lower average revenue per accession.

Board of Patent Appeals Denies Rehearing Request On Enzo BioChem Interference Patent

The Board of Patent Appeals and Interferences of the U.S. Patent and Trademark Office has denied a request for rehearing filed by Siemens Healthcare Diagnostics in a patent interference proceeding related to Enzo Biochem's Life Science's application for nucleic acid signal amplification and a Siemens patent relating to branched DNA diagnostic systems.

Siemens filed the rehearing request in response to a Feb. 22, 2010, decision by the patent office awarding priority of the invention to Enzo, based in New York City. The result of this latest decision is that the judgment of the patent office is now final. Subject to any appeals that Siemens might file in federal court, Enzo will receive a full 17-year patent for all the invention covered by the claim, commencing on the date of the patent's issuance.

"This technology is the basis for a number of significant products in clinical diagnostics and in the life sciences field which currently are marketed or licensed by various commercial entities," said Elazar Rabbani, Ph.D., chairman and CEO of Enzo. "Additionally, we plan to expand the application of this key technology beyond the scope of gene-based applications into the field of immunodiagnostics."

According to trade reports, industrywide annual sales of diagnostic products utilizing the nucleic acid signal amplification technology are estimated to exceed $100 million in the United States. Using Enzo's signal amplification technology, direct detection of nucleic acid can be carried out without the need for target amplification and without compromising the sensitivity of the detection assay.

HDL Settles Lawsuit With Berkeley HeartLab

Health Diagnostic Laboratory (Richmond, Va.) will pay Berkeley HeartLab (Alameda, Calif.) $7 million to settle a lawsuit that accused it of stealing customer accounts and trade secrets.

The settlement was announced by Celera Corp., the parent company of Berkeley HeartLab (BHL). The BHL lawsuit, filed earlier this year, has accused HDL, Blue Wave Healthcare Consultants Inc., and seven former BHL employees of allegedly stealing trade secrets, proprietary information, and clients.

The agreement calls for HDL to pay BHL $3.8 million in 2010 and the remainder in 2011. The agreement also provides for HDL to pay BHL an additional amount in 2011 based on samples HDL receives during 2010 from an agreed-upon set of health care providers.

In addition, the settlement agreement prohibits HDL and the employees from performing lab-testing services for health care providers that had been BHL customers during the latter half of 2009. HDL, Blue Wave, and the individuals named in the litigation are also prohibited from soliciting or hiring BHL employees for a defined period, subject to certain agreed-upon exceptions.

Building a Molecular Diagnostics Lab at National Jewish Health

When National Jewish Health (Denver) started a molecular diagnostics laboratory in 2008, executives decided to focus on five key growth areas: allergy and immunology, cardiovascular disease, chronic lung disease, respiratory infections, and lung cancer.

Key Lessons Learned in Growing Molecular Diagnostic Testing

- Have a clinical champion on staff.
- Be sure you have sufficient validation samples.
- Be patient.
- Clearly identify your target market, existing client base, and market opportunity universe.
- Establish your business model.
- Build alliances. Don't rely on a single growth model.
- Continue to expand and improve your products and services.
- Develop metrics to monitor and track your success.
- Take a moment to celebrate your achievements.

The strategy appears to be paying off, with the organization anticipating significant molecular diagnostic (MDx) growth over the next few years, according to Gary Smith, executive director of NJH's Advanced Diagnostic Laboratories (ADx). Smith discussed growth of the MDx lab during Washington G-2 Reports' Molecular Diagnostics Conference, held April 14-16 in Cambridge, Mass.

"We predict very nice growth, much greater than 12 percent a year over the next three years," he said.

Over 60 percent of the lab's MDx revenues come from clinical trials and clinical testing. The lab boasts a worldwide client base, with clients currently in the United States and 11 other countries. By the end of fiscal 2011, Smith anticipates clients from at least 20 countries. Clients include hospitals and reference labs, physicians, public health agencies, pharmaceutical and biotechnology firms, medical device companies, and government agencies.

"We're also trying to tiptoe into the direct-to-consumer market, although we're finding that's not as receptive as the other areas," he noted.

ADx anticipates that growth in the molecular diagnostics area will come from several key areas:

- **Translation of biomarkers to clinical translational tests and clinical diagnostic tests.** Translation tests are research-use only, but many of them go through further validation and become clinical diagnostic tests. One example of this is Factor XII genetic test for type III heriditary angioedema (HAE), which is characterized by recurrent angioedema attacks in various organs. This test has now moved from research only into the diagnostic area at ADx.
- **Codevelopment of tests.** ADx worked with an outside partner to develop a family air care kit to test for allergens.
- **Contract test development.** Outside businesses have contracted with ADx to develop tests, such as a nutrigenomic SNP panel.

- **Companion diagnostics codevelopment.** ADx plans to work with both diagnostic companies and pharmaceutical companies to develop companion diagnostics.

Developing a molecular diagnostic test takes patience, said Smith, explaining that the life-cycle of a new test can be lengthy. It can easily take five to 10 years for a test to be accepted. Timing is also critical—developing the right test at the right time. ADx worked on developing a test for H1N1 flu but ultimately found there was little demand for the test.

Having buy-in and support from the top levels of management is also critical for successful development of an MDx lab, said Smith.

"When the new CEO came four years ago, he came up with a 10-year strategic plan that involved personalized medicine and it contained a specific chapter about investing in laboratory diagnostics, including investing in a molecular lab, which didn't even exist at the time," explained Smith. "The commitment of the institution is key."

Focused MDx Growth Drivers

Current Focus

- RVP
- H1N1
- AMD
- Complement Genomics
- MUC5ac
- Filaggrin

Future Vision

- Oncology Program
  - Lung
  - GI
- Inflammatory Skin Desease Program
  - Filaggrin
- Companion Dx Therapeutics
  - Rheumatology
  - Cystic Fibrosis
  - Asthma
- PIDD Program
- Pharma Alliance Program

Source: Advanced Diagnostic Laboratories, National Jewish Health

MDX Lab ($M)



CONGRESS TO EXAMINE DTC GENETIC TEST KITS , *from page 1*

guidance materials regarding genetic counseling and physician consultations;

- All documents relating to the ability of the genetic tests to accurately identify consumer risk;
- All documents regarding policies for processing and use of individual DNA samples collected from consumers; and
- All documents regarding compliance with the Federal Food, Drug, and Cosmetic Act and Food and Drug Administration (FDA) regulations.

The letter requests that the information be produced by June 4.

Examination Prompted by OTC Kit

This renewed interest in DTC genetic testing was prompted by an announcement in early May that Walgreens drugstores would begin selling an over-the-counter genetic test kit manufactured by Pathway. Those plans were later put on hold pending clarification of whether the test requires approval from FDA.

Walgreens had planned to begin selling the Pathway Genomics Insight Saliva Collection Kit at most of its nearly 7,500 stores nationwide in mid-May. The product, which was expected to sell for $20 to $30, contains a small saliva collection kit, instructions, and a postage-paid envelope that customers could use to send their sample back to the Pathway Genomics laboratory. Customers could then order an individualized genetic health report for drug response ($79), prepregnancy planning ($179), health conditions ($179), or a combination of all three ($249).

According to published reports, Pathway officials believed the OTC test did not require FDA approval because the analysis would be done at the company's lab. "Our understanding under the current regulation is this test does not have to have FDA approval per se," David Becker, Pathway's chief science officer, told the *Washington Post*. "And we do not claim that it does."

But a May 10 letter from the FDA to Pathway founder and CEO James Plante indicates that the test may require FDA approval. The letter from James Woods, deputy director of patient safety and product quality in FDA's Office of In-Vitro Diagnostic Device Evaluation and Safety, states that Pathway's Genetic Health Report appears to meet the definition of a device as that term is defined in the Federal Food, Drug, and Cosmetic Act. Laboratory tests are considered medical devices and require approval by the FDA.

"We have conducted a review of our files and have been unable to identify any [FDA] clearance or approval number for the Genetic Health Report," wrote Woods. "We request that you provide us with the FDA clearance or approval number for the Genetic Health Report. If you do not believe that you are required to obtain FDA clearance or approval for the Genetic Health Report, please provide us with the basis for that determination."

In a statement released after receiving letter, Pathway said, "We respect and understand Walgreens' decision, and we are communicating with the FDA about the test."

While other companies have been selling genetic tests online and some tests for paternity and ancestry have been sold in stores, the plan by Pathway Genomics represented the boldest move yet to bring genetic testing to the mass market. Consumer and industry groups have been calling on the FDA to regulate genetic testing more aggressively, and some believe Pathway's action could prompt the FDA to increase, or at least clarify, its oversight of genetic tests.

Sharon Terry, president and CEO of the Genetic Alliance, an advocacy and research group, praised Walgreens' action, according to the *Post* report. "Walgreens is clearly acting in the interest of its customers by postponing the introduction of the Pathway product," she said. "The FDA, for its part, must be the guardian of safety and efficacy, all the while encouraging innovation and the benefits that genetics can bring to medicine."

Oversight Spotty

There are more than 1,300 genetic tests now available. Currently, DTC genetic testing is permitted in about half the states and is subject to little oversight at the federal level. In July 2006, the Government Accountability Office issued a report documenting troubling marketing practices by some DTC testing companies, and the Federal Trade Commission issued a consumer alert cautioning consumers to be skeptical about claims made by some DTC companies.

The level of scrutiny by the FDA differs markedly depending on whether the test is performed using a commercial "test kit" or a laboratory-developed test method. Whereas the FDA reviews the analytic and clinical validity and the labeling of commercial test kits before they are marketed and requires postmarket adverse-event reporting if there are problems with the kit, there is no premarket review of lab-developed tests, nor is there any requirement to report adverse events.

The American Society of Human Genetics (ASHG), in a statement issued in 2007, noted that the lack of a coherent regulatory landscape to ensure quality is not unique to genetic testing. "However, quality concerns are particularly acute in the DTC context because of the low barrier to market entry, the complexity of the information that consumers need to understand to make an informed decision, and the lack of provider scrutiny," said ASHG. "Consumers are at significant risk of selecting tests with unproven benefit, of obtaining testing services from laboratories of dubious quality, and of making decisions without timely and accurate genetic counseling."

ACLA Supports Physician Guidance

The American Clinical Laboratory Association (ACLA), responding to the Pathway controversy, issued a statement noting that it supports physician involvement and guidance in ordering genetic tests and using those results to diagnose conditions.

"When genetic services are marketed and delivered directly to the consumer—without important input before and after testing from a personal health care provider and genetic counselors—gaps in understanding can result in serious negative consequences," said ACLA. "In using or interpreting tests that are important for disease prevention, diagnosis, and monitoring, consumers should rely upon an ordering physician with whom they have a personal relationship, and results should not be communicated via long-distance consultations."

Genoptix Shares Plunge on First-Quarter Results

Shares of Genoptix (Carlsbad, Calif.) sank in May after posting lower-than-expected quarterly results. By May 25, shares had fallen to $25.46, down 34 percent from the year's high of $38.79 on April 20.

For the first quarter, the company earned $5.3 million, or 29 cents a share, compared with $5.9 million, or 33 cents a share, a year ago. Revenue grew 21 percent to $47.4 million, but higher operating expenses had a negative effect on net income. Both results were well short of Wall Street estimates, as analysts expected a profit of 42 cents per share and $53.2 million in revenue.

Spending at the company surged 41 percent in the first quarter, to $19.2 million. In a note to clients, Oppenheimer analyst Charles Rhyee said the promotion of sales representatives hurt revenue by $2 million to $3 million. Severe winter weather also hurt Genoptix's revenue. Rhyee said he believes there were positive signs in the quarter, but the shortfall means it's unlikely Genoptix can exceed its profit and revenue guidance for the year.

The company reaffirmed its fiscal 2010 earnings of $1.80 to $1.85 per share on sales of $235 million to $240 million. Analysts on average expect earnings of $1.91 per share on revenue of $237.7 million.

Genomic Health Reports Strong Revenue Increase

Genomic Health (Redwood City, Calif.) reported that revenue increased 22 percent for the first quarter of 2010, increasing from $33.9 million to $41.2 million. Product revenue from the Oncotype DX breast cancer tests contributed substantially to the results, bringing in $40.3 million during the quarter, compared to $33.4 million in the first quarter of 2009.

Net loss decreased 58 percent to $1.9 million in the first quarter of 2010 from $4.6 million in the first quarter of 2009. Basic and diluted net loss per share was 7 cents per share, compared with 16 cents per share for the same period a year ago.

Total operating expenses for the first quarter of 2010 were $43.1. million Included in operating expenses were noncash charges of $4.3 million, including $2.6 million of stock-based compensation expense and $1.7 million of depreciation and amortization expenses in the first quarter of 2010.

For full-year 2010, the company expects revenues of $180 million to $190 million, net income of up to $2 million, and test results delivered of 58,000 to 61,000.

Eye ON IMAGING

Laboratory Industry Report *is proud to announce a new feature in every monthly issue: Eye on Imaging. As more health care providers merge their diagnostic services, we believe it's worthwhile to keep an eye on developments in the diagnostic imaging industry and integrated diagnostics. We hope you agree.*

InSight Imaging to Acquire Eight Imaging Centers

InSight Health Services Holding Corp. (Lake Forest, Calif.) has signed a definitive agreement to acquire eight imaging centers in the Phoenix; El Paso, Texas; and Las Cruces, N.M., areas from subsidiaries of MedQuest Inc. and Novant Health Inc. for a total purchase price of about $8.5 million. The centers generated approximately $18.7 million in net revenues in 2009.

In a separate transaction, InSight Imaging has agreed to sell mobile imaging assets in North Carolina for approximately $9.2 million to an affiliate of MedQuest and Novant. The mobile imaging assets generated approximately $3.3 million in net revenues in 2009. The deals are expected to close in July 2010.

St. Jude Medical to Acquire LightLab Imaging

St. Jude Medical Inc. (St. Paul, Minn.), a global medical device company, and LightLab Imaging Inc. (Westford, Mass.) have signed a definitive agreement under which St. Jude will acquire LightLab, a subsidiary of Goodman Co. Ltd., for approximately $90 million in cash.

LightLab is the pioneer and leader in the development of Optical Coherence Tomography (OCT), a high-resolution diagnostic coronary imaging technology that aids physicians in the treatment of cardiovascular disease. In May, LightLab received Food and Drug Administration (FDA) clearance of the first OCT product available in the United States. OCT diagnostic imaging technology has been shown to provide imaging resolution 10 times greater than intravascular ultrasound imaging systems (IVUS) and 20 times faster image capture.

During the second half of 2010, St. Jude Medical expects the OCT platform to contribute an additional $20 million in revenue to its cardiovascular business. The OCT market is expected to growth at a double-digit compounded annual rate over the next five years.

The IVUS market is estimated to be $500 million for 2010 and is growing 10 percent to 15 percent annually. OCT coronary imaging is expected to grow at an even faster rate within this market.

Upon closing, St. Jude Medical will be the first company to offer a portfolio that includes both OCT and Fractional Flow Reserve (FFR) technology. No other OCT systems are currently available for coronary imaging.

Lab Index Gives Up Gains, Falls 13% in Last Five Weeks

The G-2 Reports' Laboratory Stock Index felt the effects of a jittery stock market in May, with the index falling 13 percent in the five weeks ended May 28, 2010. For the year, the index is down 8 percent. In comparison, the Nasdaq composite is down about half a percent, and the S&P 500 is down about 2 percent.

Just two of the publicly traded lab companies tracked by the index posted gains during the period while 11 experienced declines in their share price. Psychemedics Acton, Mass.) shares climbed 11 percent to $8.58 for a market cap of $44.59 million. Shares of **Clarient** (Aliso Viejo, Calif.) rose 9 percent to $3.03, giving it a market cap of $259.14 million.

Genoptix (San Diego) posted the biggest loss during the period, with its shares falling 30 percent to $26.66, giving it a market cap of $467 million.

Other companies experiencing significant losses during the five weeks were **Enzo Biochem (**New York City), whose shares fell 20 percent to $5.31 for a market cap of $201.7 million; **Myriad Genetics** (Salt Lake City), whose shares fell 21 percent to $18.25; and **Orchid Cellmark** (Princeton, N.J.), whose shares dropped 15 percent to $1.65 for a market cap of $49.44 million. Also experiencing declines were **Genomic Health** (Redwood City, Calif.), whose shares fell 11 percent to $15, **Quest** (Madison, N.J.), whose shares fell 9 percent to $52.75; **Medtox** Scientific (St. Paul, Minn.), whose shares fell 8 percent to $11.89; **LabCorp** (Burlington, N.C.), whose shares fell 5 percent to $75.61; **Bio-Reference Laboratories** (Elmwood Park, N.J.), whose shares fell 5 percent to $22.87; and **Neogenomics** (Fort Myers, Fla.), whose shares fell 2 percent to $1.45.

For up-to-the-minute laboratory and diagnostic firm data and financial news—go to ***www.g2reports.com***

G-2 Laboratory Stock Index



Source: The G-2 Laboratory Stock Index is tabulated weekly by Laboratory Industry Report *from the average percentage change of 13 laboratory testing service stocks.*

Percent Price Change, Five weeks ended 5/28/10

	Price	*Percent Change*
UP		
Clarient	$3.03	+ 9 %
Psychemedics	8.58	+11
DOWN		
Bio-Reference	22.87	-5
Enzo Biochem	5.31	-20
Genomic Health	15.00	-11
Genoptix	26.66	-30
Genzyme	48.65	-10
LabCorp	75.61	-5
Medtox	11.89	-8
Myriad Genetics	18.25	-21
Orchid Cellmark	1.65	-15
Neogenomics	1.45	-2
Quest	52.75	-9

INDUSTRY buzz

Life Science Companies Have Until July 21 to Apply for Therapeutic Discovery Grant

The U.S. Department of the Treasury has announced guidelines for applying for the new Therapeutic Discovery Project Program created by the new health care reform law. The program appropriates up to $1 billion in tax credits and grants to reduce the costs of therapeutic research by small and midsized life science companies, defined as having 250 or fewer employees at the time the application is submitted.

The therapeutic discovery tax credit is targeted to projects that show significant potential to produce new therapies, address unmet medical needs, reduce the long-term growth of health care costs, and advance the goal of curing cancer within the next 30 years.

More Information is available at ***www.irs.gov or www.treasury.gov***

The credit covers up to 50 percent of the cost of qualifying biomedical research, up to a maximum credit of $5 million per firm and $1 billion overall. To provide an immediate boost to biomedical research, the credit is effective for investments made in 2009 and 2010. Companies may submit applications beginning June 1, 2010, and applications must be postmarked by July 21, 2010.

References

Aurora Diagnostics 866-420-5512
Avondale Partners 615-467-3500
Berkeley HeartLab 800-432-7889
Bio-Reference Labs 201-791-3600
Clarient 888-443-3310
Diamond Reference Laboratory 909-861-6966
Enzo BioChem 212-583-0100
Genoptix 760-268-6200
Genomic Health 650-556-9300
Health Diagnostic Laboratory 877-443-5227
InSight Imaging 949-282-6000
LabCorp 800-334-5161
LightLab Imaging 978-399-1000
Medtox Scientific 800-832-3244
Myriad Genetics 801-584-3600
National Jewish Health 800-222-5864
NeoGenomics 239-768-0600
Navigenics 866-522-1585
Orchid Cellmark 800-362-8378
Pathway Genomics 877-505-7374
Psychemedics 800-628-8073
Quest Diagnostics 800-222-0446
Siemens Healthcare 847-267-5300
St. Jude Medical 800-328-9634
23andMe 212-843-8017
Westcliff Medical Laboratories 949-724-3900

LIR Subscription Order or Renewal Form

- ❑ **YES**, enter my one-year subscription to the *Laboratory Industry Report (LIR)* at the rate of $449/yr. Subscription includes the *LIR* newsletter and electronic access to the current and all back issues at *www.ioma.com/g2reports/issues/LIR*. Subscribers outside the U.S. add $100 postal.*
- ❑ AAB & NILA members qualify for special discount of 25% off — or $336.75 (Offer code LIRI1)
- ❑ I would like to save $269 with a 2-year subscription to *LIR* for $629*
- ❑ **YES**, I would also like to order the *Lab Industry Strategic Outlook: Market Trends & Analysis 2009* for $1495 ($1195 for Washington G-2 Reports subscribers). (Report #3308C)
- ❑ Check enclosed (payable to Washington G-2 Reports)
- ❑ American Express ❑ VISA ❑ Mastercard

Card #_____ Exp. Date _____

Cardholder's Signature _____

Name As Appears On Card _____

Name/Title _____

Company/Institution _____

Address _____

City _____ State_____ ZIP _____

Phone _____ Fax_____

e-mail address_____

*By purchasing an individual subscription, you expressly agree not to reproduce or redistribute our content without permission, including by making the content available to non-subscribers within your company or elsewhere.

Mail To: Washington G-2 Reports, 1 Washington Park, Suite 1300, Newark, NJ 07102-3130. Or call 973-718-4700 and order via above credit cards or fax order to 973-622-0595. **LIR 6/10**

 Laboratory Industry Report (ISSN 1060-5118) is published by Washington G-2 Reports, 1 Washington Park, Suite 1300, Newark, NJ 07102-3130. Tel: 973-718-4700. Fax: 973-622-0595. Web site: www.g2reports.com.

Kimberly Scott, Senior Editor; Dennis Weissman, Executive Editor; Heather Lancey, Designer; Beth Butler, Marketing Director; Dan Houder, CMO; Doug Anderson, VP & Publisher; Joe Bremner, President

Receiving duplicate issues? Have a billing question? Need to have your renewal dates coordinated? We'd be glad to help you. Call customer service at 973-718-4700.